WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Market Closed - Hong Kong S.E. Other stock markets 04:09:12 2026-06-05 am EDT			5-day change	1st Jan Change
32.74 ^HKD	+0.99%		-1.80%	+4.13%

Jun. 05	Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub	CI
May. 31	Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth	RE

Transcript : WuXi Biologics Inc., 2025 Earnings Call, Mar 25, 2026

Published on 03/25/2026 at 12:20 pm EDT - Modified on 03/25/2026 at 09:25 pm EDT

S&P Capital IQ

Presenter Speech
Laurence Tam (Analysts)

Good morning, everyone, for those based in China and Hong Kong, and good evening to those -- sorry, good evening to those who are based in China and Hong Kong,

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about WuXi Biologics (Cayman) Inc.

Jun. 05	Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub	CI
May. 31	Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth	RE
May. 26	Viridian Therapeutics signs manufacturing deal with WuXi Biologics for thyroid eye disease drug	RE
May. 25	WuXi Biologics to Conduct Up to $400 Million Share Buyback; Shares Up 4%	MT
May. 25	Wuxi Biologics to repurchase shares up to US$400 million in open market	RE
May. 25	WuXi Biologics Plans to Buy Back Up to US$400 Million of Shares	DJ
Apr. 24	WuXi Biologics Achieves Structural Completion and Key Equipment Arrival At Chengdu Microbial Commercial Manufacturing Site	CI
Apr. 23	WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics	CI
Mar. 25	WuXi Biologics Inc., 2025 Earnings Call, Mar 25, 2026
Mar. 24	WuXi Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 24	WuXi Biologics' Profit Climbs 46% in 2025	MT
Mar. 24	Wuxi Biologics posts FY revenue of RMB21,790.0 million	RE
Mar. 23	Wuxi Apptec proposed nomination for re-election of executive directors	RE
Mar. 13	WuXi Biologics Signs Antibody Development Deal with Earendil Labs	MT
Mar. 12	Earendil Labs and Wuxi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific Multispecific Antibodies and Adcs	CI